Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 13, 2017

Otsuka and Lundbeck assess brexpiprazole in Phase III trials for bipolar disorder

Japan-based Otsuka Pharmaceutical and Danish firm Lundbeck have started patient enrolment in two Phase III clinical trials of brexpiprazole to treat manic episodes in patients with bipolar I disorder.

Japan-based Otsuka Pharmaceutical and Danish firm Lundbeck have started patient enrolment in two Phase III clinical trials of brexpiprazole to treat manic episodes in patients with bipolar I disorder.

While the mechanism of action is unknown, brexpiprazole’s efficacy is thought to be mediated with partial agonist activity at serotonin 5-HT1A and dopamine D2, and antagonist activity at serotonin 5-HT2A receptors.

Additionally, brexpiprazole is said to have high affinity for noradrenaline alpha1B/2C receptors.

The multi-centre, randomised, double-blind Phase III trials will investigate the safety, efficacy and tolerability of brexpiprazole in patients having an acute manic episode, with or without mixed features, requiring hospitalisation.

“Brexpiprazole is said to have a high-affinity for noradrenaline alpha1B/2C receptors.”

The trial’s primary endpoint is mean change from baseline to day 21 in the Young-Mania Rating Scale (YMRS) total score, while the key secondary endpoint is similar change in Clinical Global Impression – Bipolar (CGI BP) severity-of-illness score in mania during the double-blind treatment period.

YMRS score is a clinician rating scale used to evaluate mania symptoms based on subjective reports and clinical observations of a patient’s condition.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Otsuka discovered the investigational candidate and is developing it in alliance with Lundbeck.

In July 2015, the US Food and Drug Administration (FDA) approved brexpiprazole for the treatment of schizophrenia and as a combination therapy to treat major depressive disorder (MDD).

Health Canada approved brexpiprazole for schizophrenia in February this year, while the Australian Department of Health granted approval for the same indication in May.

Bexpiprazole is distributed and marketed under the brand name Rexulti in the US, Canada and Australia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy